Analysts Set Sagent Pharmaceuticals Inc (SGNT) PT at $18.44
Shares of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) have been assigned a consensus recommendation of “Hold” from the nine research firms that are covering the stock. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $18.44.
Separately, Deutsche Bank AG cut Sagent Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 11th.
Institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. increased its stake in shares of Sagent Pharmaceuticals by 13.3% in the first quarter. Prudential Financial Inc. now owns 265,599 shares of the company’s stock worth $3,232,000 after buying an additional 31,200 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of Sagent Pharmaceuticals by 0.8% in the first quarter. BlackRock Fund Advisors now owns 2,291,406 shares of the company’s stock worth $27,886,000 after buying an additional 19,031 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Sagent Pharmaceuticals by 44.4% in the first quarter. Goldman Sachs Group Inc. now owns 167,978 shares of the company’s stock worth $2,044,000 after buying an additional 51,622 shares during the last quarter. Bogle Investment Management L P DE purchased a new stake in shares of Sagent Pharmaceuticals during the first quarter worth approximately $499,000. Finally, Kennedy Capital Management Inc. increased its stake in shares of Sagent Pharmaceuticals by 80.5% in the first quarter. Kennedy Capital Management Inc. now owns 473,273 shares of the company’s stock worth $5,760,000 after buying an additional 211,069 shares during the last quarter.
Sagent Pharmaceuticals Company Profile
Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.
Receive News & Stock Ratings for Sagent Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.